Beacon Pointe Advisors LLC Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Beacon Pointe Advisors LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 290.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,579 shares of the medical device company’s stock after buying an additional 16,790 shares during the period. Beacon Pointe Advisors LLC’s holdings in DexCom were worth $1,686,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Baillie Gifford & Co. lifted its holdings in DexCom by 297.4% in the 2nd quarter. Baillie Gifford & Co. now owns 18,099,399 shares of the medical device company’s stock valued at $1,348,948,000 after purchasing an additional 13,545,106 shares in the last quarter. Jennison Associates LLC lifted its holdings in DexCom by 229.3% in the 2nd quarter. Jennison Associates LLC now owns 8,563,611 shares of the medical device company’s stock valued at $638,246,000 after purchasing an additional 5,963,328 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in DexCom by 333.0% in the 2nd quarter. Clearbridge Investments LLC now owns 5,707,510 shares of the medical device company’s stock valued at $425,381,000 after purchasing an additional 4,389,431 shares in the last quarter. Brown Advisory Inc. lifted its holdings in DexCom by 153.8% in the 2nd quarter. Brown Advisory Inc. now owns 3,424,424 shares of the medical device company’s stock valued at $342,285,000 after purchasing an additional 2,075,278 shares in the last quarter. Finally, Swiss National Bank increased its stake in shares of DexCom by 301.1% during the 2nd quarter. Swiss National Bank now owns 1,684,176 shares of the medical device company’s stock valued at $125,522,000 after acquiring an additional 1,264,332 shares during the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. StockNews.com assumed coverage on shares of DexCom in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Barclays assumed coverage on shares of DexCom in a research note on Monday, October 17th. They set an “equal weight” rating and a $103.00 price objective for the company. Cowen upped their price objective on shares of DexCom from $85.00 to $114.00 in a research note on Friday, October 28th. Stifel Nicolaus upped their price objective on shares of DexCom from $112.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, October 7th. Finally, Citigroup upped their price objective on shares of DexCom from $105.00 to $117.00 in a research note on Friday, October 28th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.24.

DexCom Stock Up 1.7 %

Shares of NASDAQ:DXCM opened at $112.92 on Thursday. The company has a quick ratio of 3.43, a current ratio of 3.77 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52-week low of $66.89 and a 52-week high of $152.62. The company has a 50 day moving average of $100.97 and a two-hundred day moving average of $87.73. The company has a market capitalization of $43.62 billion, a price-to-earnings ratio of 208.15, a price-to-earnings-growth ratio of 4.26 and a beta of 1.21.

Insider Buying and Selling at DexCom

In other DexCom news, CFO Jereme M. Sylvain sold 2,400 shares of the stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $112.62, for a total value of $270,288.00. Following the completion of the sale, the chief financial officer now owns 67,237 shares of the company’s stock, valued at $7,572,230.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.41% of the stock is owned by corporate insiders.

DexCom Company Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.